Pfizer Inc. / Analyst ratings
Price targets
Analyst ratings
5 analysts rated this company in the past 90 days. The average target price is €24.69, this is a change of +19.2% compared to the current price.
-
Jefferies raises Pfizer target to $34 - 'Buy'
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies raised its price target for Pfizer from $33 to $34 and maintained its "Buy" rating. Analyst Akash Tewari described the Metsera acquisition as a good, value-enhancing deal in his commentary published Wednesday./rob/ag/tav
Publication of the original study: September 23, 2025 / 7:41 p.m. / Time zone not specified in the study
First distribution of the original study: September 23, 2025 / 7:41 p.m. / Time zone not specified in the study
Note: Information on the disclosure obligation for conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Pfizer at 'Neutral' - target $30
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating on Pfizer at "Neutral" with a price target of $30 on the planned acquisition of Metsera. Gaining a foothold in the weight-loss drug market has been a focus of the US company in recent years, Chris Schott wrote on Monday. With Metsera, Pfizer is likely to gain momentum in this area thanks to its portfolio of active ingredients in early and advanced clinical research. The deal is likely to be well received by investors.
Publication of the original study: September 22, 2025 / 7:14 a.m. / EDT First distribution of the original study: September 22, 2025 / 7:17 a.m. / EDT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains Pfizer's 'Hold' rating - target $25
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Hold" rating for Pfizer with a price target of $25. In a study published Wednesday, analyst Luisa Hector includes AstraZeneca, AbbVie, Sanofi, and the recently upgraded Novo Nordisk stock among her buy recommendations. In her analysis, she compared the industry situation with that five years ago, when the valuation was initiated. Innovations in the area of obesity, in particular, have created value since then. Drug prices and the need to offset expiring patents are currently a constant topic of discussion. Valuations are at an all-time low relative to the market. However, Hector believes the mood among investors is excessively negative./tih/tav
Publication of the original study: September 16, 2025 / 4:32 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Pfizer at 'Neutral' - target $25
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Pfizer at "Neutral" with a price target of USD 25. The pharmaceutical company significantly exceeded expectations across the board, Trung Huynh wrote on Tuesday in its second-quarter report. Cost efficiency has led to the expected increase in the earnings per share forecast./rob/ajx/he
Publication of the original study: August 5, 2025 / 11:28 a.m. / GMT. First distribution of the original study: August 5, 2025 / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Pfizer at 'Neutral' - target $30
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Pfizer at "Neutral" with a price target of $30 following its quarterly results. Chris Schott praised the pharmaceutical company for presenting unexpectedly strong figures and raising its annual outlook, praised in an initial response released Tuesday. He considers the stock to be reasonably priced./rob/edh/mis
Publication of the original study: August 5, 2025 / 7:16 a.m. / EDT
First distribution of the original study: August 5, 2025 / 7:16 a.m. / EDT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Pfizer at 'Neutral' - target $30
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Pfizer at "Neutral" with a price target of $30. The pharmaceutical company's revenue and earnings (EPS) are expected to be slightly better than market expectations, wrote Chris Schott in an outlook on the second-quarter results released Tuesday. During the analyst conference, the expert will listen for comments on margin trends, the outlook for COVID-19 products, and statements on capital allocation./rob/edh/tih
Publication of the original study: July 7, 2025 / 9:01 PM / EDT
First distribution of the original study: July 8, 2025 / 12:15 AM / EDT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Pfizer at 'Neutral' - target $25
ZURICH (dpa-AFX Analyst) - Following an investor meeting, the Swiss bank UBS maintained its rating for Pfizer at "Neutral" with a price target of USD 25. The focus was on breast cancer drugs, Trung Huynh wrote in a study released Thursday. Opportunities in this area with CDK4 and KAT6 inhibitors have been highlighted./tih/men
Publication of the original study: June 12, 2025 / 6:28 PM / GMT
First distribution of the original study: June 12, 2025 / 6:28 PM / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Bernstein maintains Pfizer at 'Market-Perform' - Target $30
NEW YORK (dpa-AFX Analyst) - US analyst Bernstein Research has maintained its rating for Pfizer at "Market-Perform" with a price target of $30. "Prevention is always the best medicine," analyst Justin Smith said in his industry commentary published Wednesday, championing vaccines. He noted that vaccines are expected to continue to be the segment of the biopharmaceutical industry with the highest barriers to entry and the strongest value potential. He therefore forecasts a four percent annual sales increase in this sector through 2034. To profit from this, he recommends Sanofi and GSK in particular. He is more cautious about Pfizer due to the US Inflation Reduction Act (IRA) and expiring patents./tih/ag
Publication of the original study: June 3, 2025 / 8:07 a.m. / UTC
First distribution of the original study: June 4, 2025 / 4:00 a.m. / UTC
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Pfizer at 'Neutral' - target $30
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan maintained its rating for Pfizer at "Neutral" with a price target of $30 at the ASCO Cancer Research Conference. According to his commentary on Monday, Chris Schott continues to view the pharmaceutical company's oncology pipeline as interesting. The expert pointed to several product candidates that are likely to achieve their goals, although the study data are still at an early stage./rob/edh/ag
Publication of the original study: June 2, 2025 / 6:41 PM / EDT
First distribution of the original study: June 2, 2025 / 6:41 PM / EDT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg lowers Pfizer target to $25 - 'Hold'
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has lowered its price target for Pfizer from $28 to $25 and maintained its "Hold" rating. Since new drugs are not yet offsetting the losses from patent expiration on established drugs, no sales growth is expected from the pharmaceutical company until 2028, wrote Kerry Holford in a study released Thursday. She initially wants to wait until the company makes progress with its drug pipeline./rob/mis/ajx
Publication of the original study: May 29, 2025 / 9:56 a.m. / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies raises target for Pfizer to $33 - 'Buy'
NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has raised its price target for Pfizer from $32 to $33 in light of the company's licensing of a cancer drug from China. Analyst Akash Tewari maintained the rating at "Buy" in a report published Wednesday, stating that he believes this is a smart move for the pharmaceutical company. There are encouraging initial clinical data on the drug.
Publication of the original study: May 21, 2025 / 8:12 a.m. / ET First distribution of the original study: May 21, 2025 / 8:12 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Pfizer's 'Buy' rating - target $32
NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has maintained its rating for Pfizer at "Buy" with a price target of $32 after the company released its earnings results. While the company narrowly missed the consensus on revenue, the pharmaceutical company performed better overall than expected, analyst Akash Tewari wrote in a report released Tuesday. This was primarily due to lower costs. Despite the current uncertainties, he still considers this year's targets to be achievable.
Publication of the original study: April 29, 2025 / 4:08 p.m. / ET. First distribution of the original study: April 29, 2025 / 4:08 p.m. / ET.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Pfizer at 'Neutral' - target $30
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Pfizer at "Neutral" after the company's earnings results, with a price target of $30. The pharmaceutical company largely met expectations in terms of sales, analyst Chris Schott wrote in a report released Tuesday. However, he mentioned that solid cost management leaves room for improvement in his own estimates.
Publication of the original study: April 29, 2025 / 4:11 p.m. / EDT First distribution of the original study: April 29, 2025 / 4:11 p.m. / EDT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Pfizer at 'Neutral' - target $24
ZURICH (dpa-AFX Analyst) - Swiss bank UBS maintained its rating for Pfizer at "Neutral" with a price target of USD 24 following its first-quarter results. Sales missed the consensus estimate by two percent, analyst Trung Huynh wrote in a study released Tuesday. The drugs Comirnaty and Vyndaqel offset the pharmaceutical company's otherwise weak product portfolio. Earnings per share significantly exceeded market expectations./bek/he
Publication of the original study: April 29, 2025 / 11:46 AM / GMT. First distribution of the original study: April 29, 2025 / 11:46 AM / GMT.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies lowers Pfizer target to $32 - 'Buy'
NEW YORK (dpa-AFX Analyser) - The analysis house Jefferies has lowered the price target for Pfizer from 34 to 32 US dollars, but left the rating at "Buy". The halt to studies for the GLP-1 weight-loss drug danugliprone is another frustrating blow to the credibility of the pharmaceutical company's management, wrote analyst Akash Tewari in a study published Monday.
Publication of the original study: April 14, 2025 / 12:21 PM / ET
First distribution of the original study: April 14, 2025 / 12:21 PM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Pfizer at 'Neutral' - target $24
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Pfizer at "Neutral" with a price target of USD 24. While the halt in studies for the GLP-1 weight-loss drug danugliprone is likely to have only a limited impact on the pharmaceutical company's share price from a fundamental perspective, analyst Trung Huynh wrote in a study published Monday, the shares could nevertheless come under pressure in the short term. Investors must now reassess the risk-return ratio, as it is now less predictable to what extent sales growth will support the planned distributions./la/ck
Publication of the original study: April 14, 2025 / 2:08 p.m. / GMT
First distribution of the original study: April 14, 2025 / 2:08 p.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Pfizer at 'Neutral' - target $30
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Pfizer at "Neutral" with a price target of $30. Market expectations for the GLP-1 weight-loss drug danugliprone are likely not yet too high, analyst Chris Schott wrote on Monday on the occasion of a research pause. Overall, he considers the American stock to be cheap./ag/la
Publication of the original study: April 14, 2025 / 8:13 a.m. / EDT
First distribution of the original study: April 14, 2025 / 8:13 a.m. / EDT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Pfizer's 'Buy' rating - target $34
NEW YORK (dpa-AFX Analyst) - Research firm Jefferies has maintained its "Buy" rating for Pfizer with a price target of $34. Analyst Akash Tewari wrote in a report released Tuesday that there were two pieces of positive news regarding the weight-loss drug danugliprone last month. Andrew Baum, the pharmaceutical company's manager responsible for strategy and innovation, expressed great confidence that the company will be able to increase the efficacy of danugliprone. In addition, the Americans have launched a new study testing the efficacy of the drug in combination with a specific GIPR antagonist./la/bek
Publication of the original study: April 7, 2025 / 6:27 PM / ET
First distribution of the original study: April 7, 2025 / 6:27 PM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Pfizer at 'Neutral' - target $30
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Pfizer at "Neutral" with a price target of $30 ahead of first-quarter results. Analyst Chris Schott believes his quarterly estimates are below consensus in a study released Friday, citing, among other things, the Covid-19 drug Paxlovid and the dynamics in benefits for Part D patients of the US health insurance program Medicare. However, he sees himself slightly above the consensus for the full year.
Publication of the original study: April 3, 2025 / 6:54 p.m. / EDT. First distribution of the original study: April 4, 2025 / 12:15 a.m. / EDT.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg lowers Pfizer target to $28 - 'Hold'
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has lowered its price target for Pfizer from $29 to $28 and maintained its "Hold" rating. Given the challenging business environment, the shares are unlikely to experience any further gains, analyst Kerry Holford wrote in a report released Friday. Medicare reform in the US and price negotiations caused some headwinds for the drug Eliquis 2026./mis/jha/
Publication of the original study: March 6, 2025 / 3:59 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman lowers Pfizer target to $32 - 'Buy'
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs lowered its price target for Pfizer from $33 to $32, but maintained its "Buy" rating. Analyst Chris Shibutani adjusted his valuation model on Wednesday to reflect the pharmaceutical company's annual report. The focus now shifts to study results and portfolio strategy./ag/nas
Publication of the original study: February 5, 2025 / 2:20 a.m. / EST
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS lowers Pfizer target to $28 - 'Neutral'
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has lowered its price target for Pfizer from $29 to $28, but left its rating at "Neutral." Analyst Trung Huynh wrote in his second commentary on the results, released Wednesday, that the fourth quarter was solid but uneventful./ag/nas
Publication of the original study: February 5, 2025 / 2:31 a.m. / GMT
First distribution of the original study: February 5, 2025 / 2:31 a.m. / GMT
Note: Information on the disclosure obligation for conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Pfizer at 'Neutral' - target $30
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Pfizer at "Neutral" with a price target of $30. Pfizer has once again exceeded expectations, wrote analyst Chris Schott in his response to the pharmaceutical company's results and follow-up questions on Wednesday. This was thanks to the coronavirus vaccine Comirnaty and the blood thinner Eliquis. However, research expenses were also significantly lower./ag/nas
Publication of the original study: February 5, 2025 / 1:41 AM / EST
First distribution of the original study: February 5, 2025 / 1:41 AM / EST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Pfizer's 'Buy' rating - target $33
NEW YORK (dpa-AFX Analyst) - Following Pfizer's fourth-quarter results, analyst Jefferies maintained its "Buy" rating with a price target of $33. The pharmaceutical company exceeded expectations in terms of sales and earnings, primarily due to Covid-19 drugs, the anticoagulant Eliquis, and the cancer drug Ibrance, analyst Akash Tewari wrote in a report released Tuesday. The RSV vaccine Abrysvo, on the other hand, significantly missed expectations. Tewari assumes that the targets for 2025 are achievable given these circumstances./tih/he
Publication of the original study: February 4, 2025 / 12:24 PM / ET First distribution of the original study: February 4, 2025 / 12:24 PM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Pfizer at 'Neutral' - target $29
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Pfizer at "Neutral" after the company's earnings release, with a price target of $29. The fourth quarter was solid at first glance, wrote analyst Trung Huynh in a report released Tuesday. He also referred to the pharmaceutical company's confirmed outlook for the full year 2025./tih/he
Publication of the original study: February 4, 2025 / 12:57 / GMT First distribution of the original study: February 4, 2025 / 12:57 / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Pfizer at 'Neutral' - target $30
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan maintained its rating on Pfizer at "Neutral" with a price target of $30 following fourth-quarter results. The results exceeded expectations, analyst Chris Schott wrote in an initial assessment released Tuesday. The result was supported by the Comirnaty coronavirus vaccine and lower operating costs. The pharmaceutical company has confirmed its outlook for the new fiscal year.
Publication of the original study: February 4, 2025 / 9:03 a.m. / EST
First distribution of the original study: February 4, 2025 / 9:03 a.m. / EST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Pfizer at 'Neutral' - target $31
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Pfizer at "Neutral" with a price target of USD 31. While the termination of the lung cancer trial with the antibody sasanlimab was for strategic reasons, the high dropout rates are worrying, wrote analyst Trung Huynh in his commentary published Thursday. He also draws negative conclusions for the bladder cancer study, which is already in Phase III./ag/ck
Publication of the original study: December 18, 2024 / 10:25 PM / GMT
First distribution of the original study: December 18, 2024 / 10:25 PM / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Pfizer's 'Buy' rating - target $33
NEW YORK (dpa-AFX Analyst) - Research firm Jefferies has maintained its "Buy" rating for Pfizer with a price target of $33. The pharmaceutical company's outlook has exceeded its and investors' expectations, wrote analyst Akash Tewari in a report released Tuesday. Thanks to the potential of anti-obesity drugs, he expressed continued satisfaction with the stock's prospects for 2025./tih/mis
Publication of the original study: December 17, 2024 / 11:52 AM / ET
First distribution of the original study: December 17, 2024 / 11:52 AM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Pfizer at 'Neutral' - target $31
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Pfizer at "Neutral" with a price target of USD 31. The pharmaceutical company's outlook for 2025 held no surprises, wrote analyst Trung Huynh in an initial reaction released Tuesday./edh/tih
Publication of the original study: December 17, 2024 / 12:48 / GMT
First distribution of the original study: December 17, 2024 / 12:48 / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Pfizer at 'Neutral' - target $30
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Pfizer at "Neutral" with a price target of $30. The revenue and earnings targets for 2025 are largely in line with expectations, analyst Chris Schott wrote in his commentary on Tuesday. Overhead signals are lower and indicate savings./ag/bek
Publication of the original study: December 17, 2024 / 7:04 a.m. / EST
First distribution of the original study: December 17, 2024 / 7:04 a.m. / EST
Note: Information on the disclosure obligation for conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Pfizer at 'Neutral' - target $30
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Pfizer at "Neutral" with a price target of $30 ahead of its 2025 forecasts. Analyst Chris Schott forecast revenue of $62.4 billion in a study released Thursday, which is below the consensus estimate./bek/gl
Publication of the original study: December 11, 2024 / 8:54 p.m. / EST. First distribution of the original study: December 12, 2024 / 12:15 a.m. / EST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg raises target for Pfizer to $29 - 'Hold'
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg raised its price target for Pfizer from $27 to $29, but maintained its "Hold" rating. Analyst Kerry Holford justified the new price target in his commentary published Friday with higher estimates for the mono- and combination Covid-19 vaccine. However, she continues to consider the pharmaceutical company's drug development uninspiring./edh/ag
Publication of the original study: November 29, 2024 / 5:55 a.m. / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Pfizer at 'Neutral' - target $31
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Pfizer at "Neutral" with a price target of USD 31 following a UBS conference. After a mixed year so far, the pharmaceutical company is regaining investor confidence, wrote analyst Trung Huynh in a study published Thursday./mis/men
Publication of the original study: November 14, 2024 / 03:33 / GMT
First distribution of the original study: November 14, 2024 / 03:33 / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Pfizer at 'Neutral' - target $31
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Pfizer at "Neutral" with a price target of USD 31 following an investor event. The pharmaceutical company has demonstrated the potential of the drug ponsegromab for cancer cachexia, analyst Trung Huynh wrote in a study released Friday. Pfizer now plans to provide in-depth insights into a product from its development pipeline once a quarter./tih/he
Publication of the original study: November 1, 2024 / 5:41 PM / GMT. First distribution of the original study: November 1, 2024 / 5:41 PM / GMT.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman raises Pfizer target to $33 - 'Buy'
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs raised its price target for Pfizer from $32 to $33 and maintained its "Buy" rating. Investors interpreted it as a signal of weakness that the 2024 sales estimate for Paxlovid was raised by $2 billion, while group sales were only raised by $1.5 billion, wrote analyst Chris Shibutani in his commentary on the quarterly report published Wednesday. However, Pfizer expressed confidence regarding its research and development activities./ag/edh
Publication of the original study: October 30, 2024 / 5:38 a.m. / EDT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Pfizer's 'Buy' rating - target $33
NEW YORK (dpa-AFX Analyst) - Following third-quarter results and an increase in its forecast, analyst Jefferies maintained its rating for Pfizer to "Buy" with a price target of $33. Thanks to strong sales of the Covid drug Paxlovid, the pharmaceutical company exceeded market expectations for sales and earnings per share, analyst Akash Tewari wrote in a report released Tuesday. The new targets were also a positive surprise.
Publication of the original study: October 29, 2024 / 9:59 a.m. / ET First distribution of the original study: October 29, 2024 / 9:59 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Pfizer at 'Neutral' - target $30
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Pfizer at "Neutral" with a price target of $30. In the US, the CDC's Advisory Committee on Immunization Practices has reviewed updated data for vaccines that protect adults against respiratory syncytial virus, analyst Chris Schott wrote in a study published Thursday. According to the expert, the timeline for booster vaccination remains uncertain. He remains cautious about the prospects of Pfizer's corresponding vaccine, Abrysvo.
Publication of the original study: October 24, 2024 / 3:07 PM / BST. First distribution of the original study: October 24, 2024 / 3:07 PM / BST.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Pfizer at 'Neutral' - target $30
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Pfizer at "Neutral" ahead of third-quarter results, with a price target of $30. Market expectations for the third quarter are likely to prove too low, analyst Chris Schott wrote in a report released Monday. There could certainly be room for improvement in the pharmaceutical company's annual outlook./mis/edh
Publication of the original study: October 6, 2024 / 11:11 PM / EDT
First distribution of the original study: October 7, 2024 / 12:15 AM / EDT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies lowers Pfizer target to $33 - 'Buy'
NEW YORK (dpa-AFX Analyser) - The analysis house Jefferies has lowered the price target for Pfizer from 35 to 33 US dollars, but left the rating at "Buy". In his commentary published on Friday, analyst Akash Tewari removed his estimates for the drug Oxbryta from his valuation model after the pharmaceutical company withdrew it from all markets./ajx/ag
Publication of the original study: September 26, 2024 / 10:51 PM / ET
First distribution of the original study: September 26, 2024 / 10:51 PM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Pfizer's 'Buy' rating - target $35
NEW YORK (dpa-AFX Analyst) - Research firm Jefferies maintained its "Buy" rating for Pfizer shares following the ESMO cancer congress, with a price target of $35. The pharmaceutical company has presented study data on its tumor cachexia antibody ponsegromab, analyst Akash Tewari wrote in his commentary published Tuesday. In the second phase of the study for the treatment of the metabolic disorder that occurs as a result of cancer, clinically significant weight gain was observed at the maximum dose. This is a positive signal, but success in the third phase of the study is not guaranteed./tih/ag
Publication of the original study: September 16, 2024 / 9:22 PM / ET
First distribution of the original study: September 16, 2024 / 9:22 PM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains Pfizer's 'Hold' rating - target $27
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its rating for Pfizer at "Hold" with a price target of $27 following the company's earnings results and an outlook increase. Analyst Kerry Holford raised her estimates for 2024 in a study released Friday, citing accelerated cost reductions. However, there are no changes for the years thereafter. The focus remains on meeting the company's COVID-19-related targets. Since approximately $5.5 billion still needs to be booked in the second half of the year, the pharmaceutical company's financial figures this year are significantly dependent on the end of the year./tih/mis
Publication of the original study: August 22, 2024 / 4:01 p.m. / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.